Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Rezatapopt with Acid Reducing Agents
NCT06054464Phase 1Completed
- Sponsor
- PMV Pharmaceuticals, Inc.
- Start
- Sep 2023
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of rezatapopt in solid tumor (2 arms), sponsored by PMV Pharmaceuticals, Inc. Primary endpoints: Maximum Plasma Concentration at 20 days, Area Under the Curve to the last measurable concentration at 20 days and 2 more. Started Sep 2023; status: completed.
02
Drugs
rezatapopt
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06054464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06054464.